Who are Seasonal trivalent inactivated influenza vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comparator: VAQTA™, Hepatitis A Virus, IXIARO®- Japanese Encephalitis vaccine, Healive+Havrix, V - C - C+V, Havrix+Havrix.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/seasonal-trivalent-inactivated-influenza-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Seasonal trivalent inactivated influenza vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Seasonal trivalent inactivated influenza vaccine (Seasonal trivalent inactivated influenza vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology.

marketed Inactivated viral vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Seasonal trivalent inactivated influenza vaccine (Seasonal trivalent inactivated influenza vaccine) — PATH. The vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of influenza virus, providing protection against seasonal flu infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Seasonal trivalent inactivated influenza vaccine TARGET	Seasonal trivalent inactivated influenza vaccine	PATH	marketed	Inactivated viral vaccine
Comparator: VAQTA™	Comparator: VAQTA™	Merck Sharp & Dohme LLC	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
Hepatitis A Virus	Hepatitis A Virus	Novartis	marketed	Inactivated viral vaccine	Hepatitis A Virus surface antigens
IXIARO®- Japanese Encephalitis vaccine	IXIARO®- Japanese Encephalitis vaccine	Medical University of Vienna	marketed	Inactivated viral vaccine
Healive+Havrix	Healive+Havrix	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine combination
V - C - C+V	V - C - C+V	IlDong Pharmaceutical Co Ltd	marketed	Inactivated viral vaccine
Havrix+Havrix	Havrix+Havrix	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Seasonal trivalent inactivated influenza vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/seasonal-trivalent-inactivated-influenza-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab